Exelixis (NASDAQ: EXEL)
Exelixis Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Exelixis Company Info
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
News & Analysis
Exelixis' Sales, Earnings Surge in Q3
The drugmaker reported robust results driven by its cabozantinib franchise.
1 No-Brainer Stock to Buy With $40
The midcap biotech just became an even better buy.
2 Stocks Under $30 to Buy and Hold
You don't need to be a millionaire to get started. Investing on a budget can work, too.
Is Exelixis Stock a Buy Now?
There is one key reason to consider the stock.
2 Top Biotech Stocks Defying the Bear Market
The best may be yet to come for these companies.
The Top Healthcare Stocks to Buy With $100
Both stocks have outperformed the broader market in the last 12 months.
The Smartest Stocks to Buy With $20 Right Now and Hold Forever
These companies can take investors on a lucrative ride, and all for the price of a few lattes.
2 Under-the-Radar Biotech Stocks to Buy in 2023
Companies that don't make a lot of noise can still make you a lot of money.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.